BIP Wealth LLC Buys 237 Shares of Eli Lilly and Company (NYSE:LLY)

BIP Wealth LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 31.6% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 988 shares of the company’s stock after acquiring an additional 237 shares during the period. BIP Wealth LLC’s holdings in Eli Lilly and Company were worth $875,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. Prospera Financial Services Inc increased its holdings in Eli Lilly and Company by 7.1% during the 3rd quarter. Prospera Financial Services Inc now owns 24,629 shares of the company’s stock worth $21,829,000 after acquiring an additional 1,642 shares during the period. Meeder Asset Management Inc. increased its holdings in shares of Eli Lilly and Company by 15.9% in the third quarter. Meeder Asset Management Inc. now owns 37,587 shares of the company’s stock worth $33,300,000 after purchasing an additional 5,167 shares during the period. OneAscent Financial Services LLC purchased a new stake in shares of Eli Lilly and Company in the third quarter worth $1,520,000. Knuff & Co LLC boosted its stake in Eli Lilly and Company by 12.8% during the third quarter. Knuff & Co LLC now owns 1,038 shares of the company’s stock valued at $920,000 after buying an additional 118 shares during the period. Finally, Caprock Group LLC grew its position in Eli Lilly and Company by 13.5% during the third quarter. Caprock Group LLC now owns 67,759 shares of the company’s stock worth $60,031,000 after buying an additional 8,051 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on LLY. Deutsche Bank Aktiengesellschaft dropped their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Guggenheim increased their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Berenberg Bank lifted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Wells Fargo & Company increased their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,007.94.

Eli Lilly and Company Price Performance

LLY opened at $727.57 on Tuesday. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The company has a market cap of $690.70 billion, a price-to-earnings ratio of 78.66, a price-to-earnings-growth ratio of 2.82 and a beta of 0.43. The stock has a fifty day simple moving average of $879.04 and a two-hundred day simple moving average of $870.84. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company’s revenue was up 20.4% on a year-over-year basis. During the same period last year, the business earned $0.10 earnings per share. Research analysts predict that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.